Search the Newsreel

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Celcuity Inc. announced that its newly FDA-approved drug, REVTORPYK (gedatolisib), has been included as a preferred Category 1 regimen in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines. This inclusion is for the second-line treatment of HR+/HER2- locally advanced or metastatic breast cancer …

Celcuity's stock drops 17% after delayed launch of FDA-approved breast cancer drug Revtorpyk.

Celcuity's stock fell 17% after the company announced a delay in the commercial launch of its FDA-approved breast cancer drug, Revtorpyk, now expected in late Q3 2026. This delay has prompted a law firm, Kessler Topaz Meltzer & Check LLP, to investigate potential securities …

Celcuity Inc (CELC) Institutional Confidence

The article analyzes Celcuity Inc's (CELC) institutional confidence, noting its high score of 10.00, which ranks it 1st out of 385 in the Biotechnology & Medical Research industry. Institutional shareholding is 97.67%, with a 12.26% quarter-over-quarter increase. Steven Cohen is the largest institutional shareholder.

NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP (KTMC) is investigating potential federal securities law violations by Celcuity Inc. (NASDAQ: CELC) after the company announced an unexpected delay in the commercial launch of its breast cancer therapy, Revtorpyk. This delayed timeline, relative to analyst expectations, caused …

Pomerantz investigates Celcuity over delayed cancer drug launch and stock drop

Pomerantz LLP is investigating Celcuity Inc. and its officers for potential securities fraud. This follows Celcuity's announcement of a delayed launch for its FDA-approved breast cancer drug, Revtorpyk, which caused a 17.6% drop in its stock price. The investigation will examine whether unlawful business …

Celcuity Inc. (CELC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Celcuity Inc. (NASDAQ:CELC) shareholders after the company announced a delayed commercial launch for its breast cancer therapy Revtorpyk. This delay, relative to analyst expectations, caused Celcuity's stock price to fall by 17.6% …

Celcuity Inc. Revenue Breakdown – NASDAQ:CELC

This article provides financial information for Celcuity Inc. (NASDAQ: CELC) on TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment performance. The content is primarily a navigation hub within the TradingView platform, detailing available data and tools …

Celcuity's Gedatolisib: Regulatory Win Meets Commercial Reality

Celcuity (CELC) has received FDA approval for its breast cancer drug, gedatolisib, marking a significant regulatory milestone. However, the article emphasizes that regulatory success is only the beginning, and commercial success is far from guaranteed due to intense market competition, payer scrutiny, and the …

Celcuity Inc. (CELC) Investor Outlook: Analyzing an 85% Upside Potential in the Biotech Sector

Celcuity Inc. (CELC), a clinical-stage biotech company with a $4.31 billion market cap, is drawing investor attention due to an 85% potential upside based on analyst ratings. The company is developing Gedatolisib for advanced breast and prostate cancer, backed by a licensing agreement with …

Price to sales forward of Celcuity Inc. – NASDAQ:CELC

This article provides "Price to sales forward" information for Celcuity Inc. (NASDAQ: CELC), a company in the medical specialties sector. The content appears to be a financial data snippet from TradingView, indicating the stock market, sector, and financial metrics available. It is a very …

Celcuity faces securities fraud probe after FDA delays breast cancer drug launch, shares drop 17.6%.

Pomerantz LLP is investigating Celcuity Inc. for potential securities fraud. This investigation follows the company's announcement of a delayed commercial launch for its FDA-approved breast cancer drug, Revtorpyk, which caused a 17.6% drop in Celcuity's stock price on July 15, 2026. The probe will …

With FDA approval, Celcuity sees big future for its new breast cancer drug

Minnesota-based biotech firm Celcuity received FDA approval for its new breast cancer drug, Revtorpyk, for a limited patient population. CEO Brian Sullivan believes the drug will become a "blockbuster" and a new standard of care, targeting a $6 billion market for HR+/HER2- advanced breast …

CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Celcuity (CELC) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Celcuity and would like to discuss your legal rights, contact Bragar Eagel …

CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug

Celcuity Inc. (CELC) shares surged 7% after the FDA approved its drug gedatolisib, in combination with fulvestrant, for advanced hormone receptor-positive, HER2-negative breast cancer. This approval marks Celcuity's transition from a development-stage company to one with a commercial product, and the company intends to …

Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer

Celcuity (CELC) saw a 17.4% stock drop despite FDA approval for its first-in-class drug REVTORPYK for HR-positive, HER2-negative breast cancer. The approval, based on strong progression-free survival data from the VIKTORIA-1 trial, shifts the company's focus to market uptake and managing increased debt from …

Why CELC Stock Declined 15% in a Week Despite a Major FDA Win

Despite securing FDA approval for its first marketed product, Revtorpyk, Celcuity (CELC) stock declined 15% in a week. The decline is attributed to investor disappointment over the delayed commercial launch of Revtorpyk, now set for the late third quarter of 2026, which impacts near-term …

Kirby McInerney LLP investigates Celcuity for potential securities fraud after FDA approval delays impact stock price.

Kirby McInerney LLP is investigating Celcuity Inc. for potential securities fraud. This probe follows a significant 17.6% drop in Celcuity's stock price after the company announced a delayed commercial launch for its FDA-approved breast cancer therapy, Revtorpyk, to late Q3 2026, which was later …

CELC INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Celcuity Inc. (“Celcuity” or the “Company”) (Nasdaq: CELC). The investigation concerns whether the Company and/or members of its senior management may have violated federal …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Celcuity Inc. (NASDAQ:CELC) following a significant drop in its stock price. The investigation stems from Celcuity's announcement of FDA approval for its breast cancer therapy, Revtorpyk, with an anticipated commercial launch in late Q3 …

Celcuity (CELC) Stock May Be Overvalued After REVTORPYK Approval

Despite a significant 7x return over three years and the FDA approval of REVTORPYK, Celcuity (CELC) stock appears overvalued, primarily due to its high price-to-book (P/B) ratio of 80.5x, far exceeding industry averages. The mixed valuation score suggests that current expectations already discount substantial …

Celcuity (CELC) Receives a Buy from Leerink Partners

Leerink Partners has maintained a Buy rating for Celcuity (CELC) and set a price target of $147.00. This follows Citizens JMP also maintaining a Buy rating with a $177.00 price target. The company reported a quarterly GAAP net loss of $52.84 million for the …

Precision Trading with Celcuity Inc. (CELC) Risk Zones

This article provides a detailed analysis of Celcuity Inc. (NASDAQ: CELC), highlighting weak near-term sentiment despite prevailing positive sentiment. It offers three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various risk profiles and holding periods. The report emphasizes …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

Pomerantz LLP is investigating potential securities fraud claims against Celcuity Inc. (NASDAQ: CELC) on behalf of investors. The investigation follows a significant drop in Celcuity's stock price after the company announced U.S. Food and Drug Administration approval for its breast cancer therapy Revtorpyk, with …

Celcuity's REVTORPYK Approval: A Multi-Billion Dollar Breakthrough Despite High Expectations

Celcuity Inc. secured early FDA approval for REVTORPYK (gedatolisib) for HR+/HER2- breast cancer, signaling a potential multi-billion dollar market opportunity. The drug, a first-in-class pan-PI3K/mTOR inhibitor, demonstrated superior efficacy and a favorable safety profile compared to existing treatments. Despite a significant stock rally leading …

Celcuity wins FDA approval for REVTORPYK; plans late Q3 commercial launch

Celcuity has received FDA approval for REVTORPYK (gedatolisib) to treat HR+/HER2- metastatic breast cancer without a PIK3CA mutation. The company plans a commercial launch in late Q3 2026, following a Phase 3 trial showing significant reduction in disease progression risk. Celcuity also intends to …

Celcuity’s Revtorpyk wins FDA nod in breast cancer

Celcuity Inc. received FDA approval for Revtorpyk (gedatolisib) for a subset of breast cancer patients, marking the company's first commercial product and a new treatment option. Despite this positive news, investor excitement was dampened by an unanticipated launch delay, causing Celcuity's shares (NASDAQ:CELC) to …

Celcuity gains FDA approval for closely watched breast cancer drug

Celcuity received FDA approval for its breast cancer drug, Revtorpyk, for use in specific combinations for advanced ER-positive, HER2-negative breast cancer patients without a PIK3CA mutation. Despite the approval, Celcuity's shares fell by nearly 20% due to a delayed launch timeline and unexpected discontinuation …

It Might Not Be A Great Idea To Buy Celcomdigi Berhad (KLSE:CDB) For Its Next Dividend

Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76%

Celcuity LLC stock reaches all-time high at 128.29 USD

Celcuity earnings up next as breast cancer drug nears approval

CELCUITY ($CELC) Releases Q4 2025 Earnings | CELC Stock News

Celcomdigi Berhad Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Are Celcomdigi Berhad's (KLSE:CDB) Mixed Financials Driving The Negative Sentiment?

Celcomdigi Berhad Reports Earnings Results for the First Quarter Ended March 31, 2025

CDB Shares (6947.KL) – CelcomDigi Berhad Overview & Price Forecast